Rockefeller Financial Services Inc Lowers stake in St. Jude Medical (STJ)

St. Jude Medical (STJ) : Rockefeller Financial Services Inc reduced its stake in St. Jude Medical by 2.62% during the most recent quarter end. The investment management company now holds a total of 1,436,667 shares of St. Jude Medical which is valued at $117,375,694 after selling 38,705 shares in St. Jude Medical , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.St. Jude Medical makes up approximately 2.26% of Rockefeller Financial Services Inc’s portfolio.

Other Hedge Funds, Including , Hartford Investment Management Co reduced its stake in STJ by selling 26,951 shares or 28.48% in the most recent quarter. The Hedge Fund company now holds 67,693 shares of STJ which is valued at $5,530,518. St. Jude Medical makes up approx 0.11% of Hartford Investment Management Co’s portfolio.Eagle Asset Management Inc reduced its stake in STJ by selling 98,994 shares or 7.03% in the most recent quarter. The Hedge Fund company now holds 1,308,811 shares of STJ which is valued at $106,327,806. St. Jude Medical makes up approx 0.71% of Eagle Asset Management Inc’s portfolio. Somerset Trust Co sold out all of its stake in STJ during the most recent quarter. The investment firm sold 29,004 shares of STJ which is valued $2,333,372.Capstone Asset Management Co boosted its stake in STJ in the latest quarter, The investment management firm added 2,704 additional shares and now holds a total of 80,616 shares of St. Jude Medical which is valued at $6,485,557. St. Jude Medical makes up approx 0.19% of Capstone Asset Management Co’s portfolio.

St. Jude Medical opened for trading at $80.64 and hit $81.41 on the upside on Wednesday, eventually ending the session at $81.24, with a gain of 1.28% or 1.03 points. The heightened volatility saw the trading volume jump to 17,10,260 shares. Company has a market cap of $23,095 M.

On the company’s financial health, St. Jude Medical reported $1.06 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $1.06. The company had revenue of $1562.00 million for the quarter, compared to analysts expectations of $1552.79 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on St. Jude Medical. Company shares were Downgraded by Wedbush on Jul 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 84 from a previous price target of $70 .St. Jude Medical was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016. St. Jude Medical was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on May 10, 2016.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.